Whitman Kevin
Known title: VP and ControllerCIK: 0001768114
Associated companies
Transaction History
| INFU | ▲ Buy | Option Exercise | 5,000 | $10K | 9/6/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 2,642 | $20K | 9/6/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 5,000 | $10K | 9/6/2022 | View on chart |
| INFU | ▼ Sell | Open Market | 2,642 | $20K | 9/6/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.